ERBB2 and breast cancer: Dual HER2 inhibition with trastuzumab and pertuzumab plus docetaxel has received approval as the standard of care for HER2-positive breast cancer in neoadjuvant, adjuvant, and first-line treatment by the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China, based on results from the NeoSphere, APHINITY, and CLEOPATRA trials, respectively [3, 7–9].